Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to wipe out myeloma in patients out of options

NCT ID NCT06282978

Ongoing Disease control Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer to undetectable levels in the bone marrow. The drug is given as a weekly shot, and if it works well, the dosing may be reduced to every other week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Elranatamab (a targeted antibody drug given as a shot under the skin)
What this could lead to
If successful, this could offer a new treatment option for patients with multiple myeloma that has stopped responding to other therapies, potentially achieving very deep remissions.
What could go wrong
This is an early-phase (Phase 2) study with only 50 participants, so results may not apply to all patients. The drug can cause serious side effects like cytokine release syndrome, nerve toxicity, and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE

Contacts and locations

Locations

  • C.H. de Toledo (Virgen de la Salud)

    Toledo, 45005, Spain

  • CHU de Gran Canaria Doctor Negrín

    Las Palmas de Gran Canaria, Las Palmas, 35010, Spain

  • Complejo Asistencial Universitario de León

    León, Spain

  • H. Clínic i Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clínico Universitario Salamanca

    Salamanca, 37007, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar, Murcia, 30120, Spain

  • Hospital Clínico Universitario de Santiago ~ CHUS

    Santiago de Compostela, A Coruña, 15706, Spain

  • Hospital Son Llàtzer

    Palma de Mallorca, Balearic Islands, 07198, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario de Jerez de la Frontera

    Jerez de la Frontera, Cádiz, 11407, Spain

  • Hospital de Cabueñes

    Gijón, 33394, Spain

  • Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.